Overview

Tofacitinib in Recurrent GBM Patients

Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.
Phase:
Phase 3
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
Pfizer
Treatments:
Tofacitinib